Individualization of Tamoxifen Treatment for Breast Carcinoma
Authors:
- T van GelderTGT van Gelder
- R H J MathijssenRMR H J Mathijssen
- 22 August 2012
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 92 (4) , 431-433
Abstract
Traditionally, all patients treated with tamoxifen receive a standard dose. A number of studies claimed a clinically relevant impact of cytochrome P450 2D6 (CYP2D6) genotype on outcome, and therefore genotyping before tamoxifen therapy was advocated. Recent data showed that adequate exposure to the active metabolite endoxifen is important and that genotype only partially explains interindividual differences in endoxifen concentrations. Phenotyping approaches, as well as therapeutic drug monitoring (TDM) strategies, are now being tested to individualize tamoxifen treatment.Keywords
This publication has 5 references indexed in Scilit:
- CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons LearnedJNCI: Journal of the National Cancer Institute, 2012
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter StudyJournal of Clinical Oncology, 2011
- Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen TreatmentJournal of Clinical Oncology, 2011
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in PlasmaClinical Pharmacology & Therapeutics, 2011
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer OutcomesClinical Pharmacology & Therapeutics, 2011